Sign In
Buy CTMX
$3.22
+0.0600 (+1.90%)
At Close: Jun 03, 2026
CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
08:00am, Thursday, 29'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of invest
CytomX Therapeutics Announces New Employment Inducement Grants
04:01pm, Wednesday, 14'th Apr 2021
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inve
Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls
11:47am, Monday, 29'th Mar 2021
With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
08:00am, Wednesday, 24'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inve
Moving Average Crossover Alert: CytomX Therapeutics (CTMX)
06:49am, Tuesday, 02'nd Mar 2021
CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2020 Results - Earnings Call Transcript
10:39pm, Wednesday, 24'th Feb 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2020 Results - Earnings Call Transcript
CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
08:00am, Monday, 22'nd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves
CytomX Therapeutics Announces New Employment Inducement Grant
08:00am, Friday, 19'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
08:00am, Wednesday, 17'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:19am, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming live
CytomX Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:00am, Wednesday, 03'rd Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming live
Steven Cohen Snaps Up Stake in CytomX Therapeutics
12:43pm, Wednesday, 27'th Jan 2021
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).
Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today
12:00pm, Thursday, 21'st Jan 2021
All four biotechs announced the pricing of stock offerings.
CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
09:50pm, Wednesday, 20'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming live
CytomX Therapeutics Announces Proposed Public Offering of Common Stock
04:35pm, Tuesday, 19'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives
